The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification

Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan ZhangCancer 2024 · DOI

TL;DR

This study reveals that non-small cell lung cancer (NSCLC) patients with M1c1 metastatic patterns, who receive first-line immunotherapy combined with chemotherapy, have a significantly better prognosis than those with M1c2. Furthermore, distinct serum metabolic profiles, particularly alterations in lipid metabolism, were identified before treatment and correlated with these survival differences, suggesting potential biomarkers for predicting treatment outcomes.

What Problem Does This Paper Address?

Lung cancer remains a major global health challenge. The TNM staging system is crucial for assessing severity and predicting prognosis. The recent 9th edition of the TNM classification refined the M1c stage into two subcategories: M1c1 (multiple extrathoracic lesions within a single organ system) and M1c2 (multiple extrathoracic lesions involving multiple organ systems). While evidence suggests survival differences between M1c1 and M1c2, it's unclear if these distinctions persist when patients receive first-line immunotherapy combined with chemotherapy, a standard treatment for advanced, driver gene-negative NSCLC. Moreover, reliable biomarkers to predict treatment efficacy are still needed, as PD-L1 expression alone isn't always sufficient. This paper aims to investigate the prognostic differences between M1c1 and M1c2 patients undergoing this combination therapy and to identify potential serum metabolic biomarkers associated with treatment outcomes.

Methods

The study employed a retrospective design, enrolling 33 NSCLC patients classified as M1c1 and 22 as M1c2, all lacking driver gene mutations and receiving first-line PD-1 inhibitor plus chemotherapy. Key methods included:

  • Survival Analysis: Kaplan-Meier curves and Cox regression models (univariate and multivariate) were used to analyze progression-free survival (PFS) and identify independent prognostic factors.
  • Untargeted Metabolomics: Serum samples were collected from patients before treatment initiation. Liquid chromatography-mass spectrometry (LC-MS/MS) was used for untargeted metabolomics analysis to identify differential metabolites between the M1c1 and M1c2 groups.
  • Bioinformatics Analysis: Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to assess sample stability and group discrimination. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed to identify affected metabolic pathways.
  • Biomarker Selection: Metabolites were further screened using stringent criteria (fold change > 2 or < 0.5) to identify clinically significant differential metabolites. Receiver operating characteristic (ROC) curves were used to assess the predictive performance of these metabolites.

Datasets

The study utilized serum samples from 55 NSCLC patients diagnosed at Shanghai Chest Hospital between January 2019 and December 2021. These samples were divided into two groups based on their M1c classification (M1c1 and M1c2) according to the 9th edition of the TNM Classification. No new benchmarks were introduced; the study focused on analyzing existing patient data.

Key Insights and Ideas

  • M1c Subclassification Matters for Prognosis: The refined M1c classification into M1c1 and M1c2 is not just an anatomical distinction; it has significant prognostic implications, even when patients receive the same standard-of-care treatment.
  • Lipid Metabolism as a Prognostic Indicator: Pre-treatment serum metabolomics revealed distinct metabolic profiles between M1c1 and M1c2 patients. Notably, alterations in lipid metabolism, specifically reduced levels of diacylglycerol and sphingomyelin, were associated with poorer outcomes in the M1c2 group. This suggests that lipid dysregulation might play a role in tumor metastasis and invasion.
  • Potential for Novel Biomarkers: The identified differential metabolites, particularly those related to lipid metabolism, show promise as potential blood-based biomarkers for predicting treatment response and prognosis in NSCLC patients receiving immunotherapy.

Key Results

  • Survival Disparity: NSCLC patients in the M1c1 group had a significantly longer median PFS (16.0 months) compared to the M1c2 group (9.0 months) (p=0.017). This difference was also significant in multivariate analysis (HR=0.45, p=0.028).
  • Metabolic Pathway Alterations: M1c2 patients with unfavorable outcomes showed distinct metabolic pathway changes before treatment, including alterations in platelet activation, linoleic acid metabolism, and the VEGF signaling pathway.
  • Differential Metabolites Identified: Preliminary screening identified 185 differential metabolites, with 125 downregulated and 60 upregulated in the M1c2 group.
  • Predictive Metabolites: Dihexanoyl-sn-glycerol and Sphingosine 1-phosphate demonstrated superior predictive performance (AUC > 0.7) and were significantly decreased in the M1c2 group.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study included a relatively small cohort (33 M1c1, 22 M1c2), which limits the generalizability of the findings.
  • Focus on M1c Disease: The study was limited to M1c disease, which might introduce bias. Future work should include data from M1a and M1b stages for broader comparisons.
  • Retrospective Design: The retrospective nature of the study has inherent limitations, and the follow-up time might not be sufficient to observe overall survival.
  • Need for Validation: While untargeted metabolomics identified numerous differential metabolites, subsequent validation experiments are necessary to confirm their clinical significance.

Future work should focus on larger, prospective studies to validate these findings, explore the role of these metabolic alterations in tumor progression and treatment resistance, and potentially develop these identified metabolites into clinically useful biomarkers for NSCLC patients.

Summary updated

Abstract

NSCLC patients in M1c1, devoid of driver gene mutations, receiving first-line PD-1 inhibitors combined with chemotherapy, experienced superior outcomes compared to M1c2 patients. Moreover, metabolomic profiles strongly correlated with the prognosis of these patients, and M1c2 patients with unfavorable outcomes manifested distinct changes in metabolic pathways before treatment. These changes predominantly involved alterations in lipid metabolism, such as decreased diacylglycerol and sphingomyelin, which may impact tumor migration and invasion.
BibTeX
@inproceedings{zheng2024prognosis,
  author = {Liang Zheng and Fang Hu and Wei Nie and Jun Lu and Bo Zhang and Jianlin Xu and Shuyuan Wang and Ying Li and Xiaoxuan Zheng and Wei Zhang and Yinchen Shen and Runbo Zhong and Tianqing Chu and Baohui Han and Hua Zhong and Xueyan Zhang},
  title = {{The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.70223},
}
Figure